What happens if my GLP-1 provider shuts down?
Your money and your medication follow different rules. Billing: subscriptions end, but prepaid balances become creditor claims — one more reason the refund clause and short commitments matter (the prepaid guide). Medication: your prescription lives at the fulfilling pharmacy, not the platform, which is a quiet argument for programs that name their pharmacies; a named pharmacy can sometimes continue a fill or transfer records while an anonymous one simply vanishes with the brand. Continuity: the switching sequence (playbook here) runs the same in an emergency, just faster — qualify a destination, overlap shipments, document everything. In a market that has already seen exits and pivots, portability is a feature worth paying nothing extra for.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
The market this answer lives in, at the 2026-08-09 capture: verified compounded tirzepatide runs $215–$597 a month all-in across 17 programs, with the floor at NexLife↗ (dose-flat, no membership); the approved-product benchmark is Zepbound (LillyDirect↗) at $449 maintenance; and any real insurance coverage beats every cash figure named anywhere on this page.
How to use figures like these well: treat any advertised price without a maintenance-dose figure as a starter teaser; fold every mandatory membership into the total before comparing; read prepaid rates as commitments, not monthly prices; and check the capture date, because a GLP-1 price without a date is a rumor. Those four habits, applied consistently, are most of what separates this database from the marketing it indexes — the full basis definition is in the methodology, and the sortable field is in the price database.
The wider board this answer sits on: verified compounded floors of $215 (tirzepatide) and $133 (semaglutide), brand direct channels at $449 and $349 with the oral pill from $149, and insurance — where it exists — beating all of it. Prices here have only fallen for three straight years, which quietly argues for short commitments and periodic re-shopping; the price-history analysis makes that case with dates.
Basis for every figure: all-in monthly price (medication + mandatory fees) at the maintenance dose, captured from provider pages on the dates in the database. Not medical advice.